Active Ingredient History
Cenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor (rhNGF), is a recombinant form of human nerve growth factor (NGF). In July 2017, it was approved in the European Union as an eye drop formulation for the treatment of moderate or severe neurotrophic keratitis in adults. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Keratitis (approved 2018)
Alzheimer Disease (Phase 4)
Brain Injuries (Phase 2)
Brain Injuries, Traumatic (Phase 4)
Cerebral Palsy (Phase 2)
Cerebral Small Vessel Diseases (Phase 4)
Corneal Ulcer (Phase 1/Phase 2)
Dementia, Vascular (Phase 4)
Diabetes Mellitus (Phase 1/Phase 2)
Dry Eye Syndromes (Phase 3)
Glaucoma (Phase 1)
Healthy Volunteers (Phase 1)
HIV Infections (Phase 2)
Hyperalgesia (Early Phase 1)
Ischemic Stroke (Phase 4)
Keratitis (Phase 4)
Macular Edema (Phase 2)
Mental Disorders (Phase 2)
Optic Nerve (Phase 1)
Pain (Early Phase 1)
Peripheral Nervous System Diseases (Phase 2)
Retinitis Pigmentosa (Phase 2)
Speech Disorders (Phase 2)
Stroke (Phase 4)
Vision, Ocular (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
